Skip to main content
Equibles
CTNM logo

CTNM · Contineum Therapeutics, Inc. · Investor Relations

Track CTNM — free

Use CTNM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTNM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.35 -0.11 (-1.30%) At close · Oct 21
Russell 2000 member Rebalance outlook locked
Market Cap
$314.14M
Shares
37.62M
Volume · Oct 21 1.12M Avg daily vol (3M) 794.68K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-14 Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint Analyses of the data, including prespecified exploratory endpoints, are ongoing SAN DIEGO --(BUSINESS WIRE)--Sep. 14, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage
2026-08-25 Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--Aug. 25, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that
2026-07-30 Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

SAN DIEGO --(BUSINESS WIRE)--Jul. 30, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its
2026-06-30 Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) - Blocking LPAR1 inhibits key steps in the fibrosis pathway with potential targets in several therapeutic indications SAN DIEGO --(BUSINESS
2026-06-01 Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--Jun. 1, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that
2026-05-15 Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--May 15, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that
2026-05-12 Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--May 12, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that
2026-05-11 Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

SAN DIEGO --(BUSINESS WIRE)--May 11, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two
2026-05-05 Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

SAN DIEGO --(BUSINESS WIRE)--May 5, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its
2026-05-01 Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO --(BUSINESS WIRE)--May 1, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that

Past events

Date Event Type
2026-09-15 Morgan Stanley 2026 Global Healthcare Conference Conference
2026-09-15 2026 Morgan Stanley Global Healthcare Conference Conference
2026-06-09 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-06-09 2026 Goldman Sachs Global Healthcare Conference Conference
2026-05-19 RBC 2026 Global Healthcare Conference Conference
2026-03-11 Leerink Global Healthcare Conference Conference

Source: https://ir.contineum-tx.com/

Key facts CIK 1855175 CUSIP 21217B100 13F (30d) 7 filings 7 filers Visit website Investor relations